Soleno Therapeutics(US:SLNO) Globenewswireยท2025-09-10 16:37Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Soleno Therapeutics securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Soleno Therapeutics [2]. Group 2: Stock Performance and Concerns - On August 15, 2025, Soleno Therapeutics' stock fell 7.4% following a short report from Scorpion Capital that raised serious concerns about its treatment for Prader-Willi syndrome, VYKAT XR [3]. - The Scorpion Capital report highlighted personal safety issues and suggested that the drug might face withdrawal from the market or a significant decline in new prescriptions [3]. - The stock experienced an additional decline of 4.9% on the next trading day after the initial drop [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].